Tirzepatide

Product Details

Parameter	Specification
Purity	≥ 99% (HPLC, third-party tested)
Form	Lyophilized peptide powder
Content	10 mg Tirzepatide per vial
Packaging	Glass vial with sterile closure
Storage Conditions	Store lyophilized at 2–8 °C (desiccated, protect from light)
Molecular Formula	C225H348N48O68
Molecular Weight	~4813.5 g·mol⁻¹
Amino Acid Sequence	Synthetic GIP/GLP-1 receptor agonist peptide with C20 fatty diacid side chain for extended activity
CAS Number	2023788-19-2
Solubility	Bacteriostatic water

Overview

Tirzepatide is a synthetic peptide belonging to a new class of dual incretin receptor agonists, acting on both GLP-1 and GIP receptors. It represents a major advancement in metabolic science as the first clinically validated molecule combining these two pathways (Frias et al., 2018; Jastreboff et al., 2022).

What it is and how it works

Tirzepatide activates: GLP-1 receptor (increases insulin secretion, reduces glucagon, slows gastric emptying, reduces appetite) and GIP receptor (enhances insulin response, improves fat metabolism, modulates energy storage). This dual action leads to: stronger metabolic effects than GLP-1 alone.

Effects confirmed by research

1. Weight loss

• up to ~15–22% reduction (Jastreboff et al., 2022).

2. Glycemic control

• strong HbA1c reduction (Frias et al., 2018).

3. Fat metabolism

• reduced visceral fat, improved lipid metabolism.

4. Cardiovascular markers

• improved lipid profile, reduced inflammation.

5. Appetite regulation

• strong satiety, reduced hunger.

Scientific description

Tirzepatide is: a dual GLP-1/GIP receptor agonist, regulator of: glucose metabolism, appetite, lipid metabolism.

References

Jastreboff, A. M., et al. SURMOUNT-1. NEJM. 2022. Frias, J. P., et al. SURPASS trials. Lancet. 2018. Drucker, D. J. Incretin biology. Cell Metabolism. 2021. Coskun, T., et al. Dual agonist mechanism. Science Translational Medicine. 2018.